Leyden Labs

Freeing humanity from the burden of respiratory viruses

Founded 2020

The Netherlands 81 employees Total: $342.50M Biotechnology, Health and Wellness +1

General Information

Company Name Leyden Labs

Founded Year 2020

Location

The Netherlands

Employees 81

Industries Biotechnology, Health and Wellness, Life Sciences

Business Model B2B, D2C, B2G

Revenue Model Product Sales, Licensing

Offices as of Oct 2026

Leiden, The Netherlands

Social

BounceWatch is an independent company data service, not affiliated with Leyden Labs. To contact Leyden Labs, visit leydenlabs.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Leyden Labs compare?

A PDF of Leyden Labs and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Leyden Labs soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Growth Metrics Oct 13, 2026

Leyden Labs has grown to a team of approximately 70 team members.

Grant Received Oct 02, 2026

Leyden Labs, alongside other companies, received backing from the HERA Invest initiative, a funding program by the Health Emergency Preparedness and Response Authority (DG HERA) and the European In…

Homepage Update Oct 01, 2026

Significant changes detected on company website (69.7% content change).

Get alerts when Leyden Labs shows new signals

AI Insight

Bounce Watch AI

2 months ago

Leyden Labs recently closed a significant €40 million Late VC funding round in June 2026, with the European Innovation Council (EIC) Fund — recognized as Europe's most active investor — among its key participants. This substantial investment, which also included the Bill & Melinda Gates Foundation, signals robust confidence in their broad-spectrum intranasal antiviral platform and its potential for global public health impact. The continuous influx of capital from diverse strategic investors empowers Leyden Labs to further accelerate its clinical development and market readiness for respiratory virus prevention.

Signal Types

Funding Market Recognition

Strategic Labels

Late-Stage Funding Biotech Growth Strategic Partnerships

Next Move: Clinical Trials

Impact: 9/10

Ideal For: Late-Stage Biotech VCs — Public Health Focus

About Leyden Labs

Leyden Labs is a Netherlands-based company founded in 2020, operating within the Biotechnology, Health and Wellness, and Life Sciences industries. Its mission, succinctly put as “Freeing humanity from the burden of respiratory viruses,” encapsulates its focus on developing intranasal solutions aimed at providing immediate protection against a broad spectrum of respiratory viruses, including influenza and coronavirus variants.

The company’s innovative approach targets viral commonalities to safeguard humanity from both existing and emerging threats. This strategy is supported by a dynamic team comprising seasoned biotech veterans and new talent committed to unconventional thinking.

Leyden Labs last secured a €40.00M late VC investment on 01 June 2026, backed by prestigious investors like the Bill & Melinda Gates Foundation, Invest-NL, ClavystBio, EIC Fund, and reanfoundation.org, underscoring strong confidence in its journey to revolutionize global health security.

Business keywords: intranasal products, respiratory viruses, virus prevention, influenza, coronavirus, viral families, infectious disease, immunology, drug development, public health, preventive medicine, innovative healthcare, antiviral products, biotech innovation

Services & Products

Development of nasal sprays for respiratory viruses

Clinical testing of antiviral compounds

Research in mucosal immunity and antibody modification

Target Customers

Healthcare providers Pharmaceutical companies Governments and public health institutions Individuals seeking preventive health measures

Funding Rounds & Investors (7)

View All

Funding Stage	Amount	Investors	Lead Investors	Date
Late VC	€40.00M	5	Bill & Melinda Gates Foundation, Invest-NL +3	01 Jun 2026
Grant	€30.00M	2	Invest-NL, EIC	01 Oct 2025
Debt Financing	€20.00M	1	European Investment Bank	01 Jun 2025
Late VC	$70.00M	10	Casdin Capital, F-Prime Capital +8	01 Jan 2025
Grant	$2.50M	1	European Innovation Council	01 Oct 2024
Series B	$140.00M	7	Casdin Capital, F-Prime Capital +5	01 Jan 2022
Series A	€40.00M	4	Casdin Capital, F-Prime Capital +2	01 Mar 2021

Latest News

View All

Leyden Labs buys RIGImmune, unveils Phase 1 nasal antiviral data

Dealroom Sep 12, 2026

Leyden Labs Reports Positive Phase 1 Results for RIG-101, Supporting Advancement into Phase 2 to Protect Asthma Patients

Business Wire Sep 09, 2026

Leyden Labs reveals RIGImmune acquisition with Phase 1 data

European-biotechnology.com Sep 09, 2026

The Netherlands' top-funded tech companies in H1 2026

Tech Sep 03, 2026

Top 10 most active investors in Europe in 2026 – so far

Eu-startups Jul 20, 2026

Leyden Labs secures €40 million to develop intranasal protection against influenza and coronaviruses

Eu-startups Jun 25, 2026

Leyden Labs Alternatives & Competitors

View All Alternatives

Leyden Labs vs

Cidara Therapeutics United States

Leading the Science of Protection

Acquired

47 employees

Biotechnology, Health Care

Compare Leyden Labs vs Cidara Therapeutics

Leyden Labs vs

Alumis United States

Transforming the lives of patients living with immune-mediated diseases using a precision approach.

Series C

249 employees

Biotechnology, Health Care

Compare Leyden Labs vs Alumis

Leyden Labs vs

ANA Therapeutics United States

We’re investigating niclosamide as a treatment for COVID-19.

Seed

2-10 employees

Biotechnology, Health Care

View all alternatives

FAQ About Leyden Labs

Freeing humanity from the burden of respiratory viruses

Leyden Labs was founded in 2020.

Leyden Labs is headquartered in The Netherlands. As of Oct 2026, it also has offices in Leiden, The Netherlands.

Leyden Labs operates in Biotechnology, Health and Wellness and Life Sciences. Its work centres on intranasal products, respiratory viruses, virus prevention and influenza. Its customers include Healthcare providers, Pharmaceutical companies and Governments and public health institutions.

Leyden Labs has a B2B, D2C and B2G business model. Its revenue comes from Product Sales and Licensing.

Leyden Labs has approximately 81 employees.

Leyden Labs has completed 7 funding rounds, raising a total of $342.50M.

Leyden Labs offers: Development of nasal sprays for respiratory viruses, Clinical testing of antiviral compounds, Research in mucosal immunity and antibody modification.

Top alternatives and competitors to Leyden Labs include Cidara Therapeutics, Alumis, ANA Therapeutics, Equigerminal, SINOVAC BIOTECH LTD.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Leyden Labs and Cidara Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Leyden Labs, https://bouncewatch.com/company/leyden-labs, updated 11 October 2026. When citing, please name BounceWatch and link this page.

Leyden Labs

General Information

Discover More

What changed at Leyden Labs recently?

AI Insight

About Leyden Labs

Services & Products

Target Customers

Funding Rounds & Investors (7)

Latest News

Leyden Labs Alternatives & Competitors

FAQ About Leyden Labs